The somatostatin analogue [111 In-DTPA-d-Phe 1]-octreotide (111 In-octreotide) allows
scintigraphic visualization of somatostatin receptor-expressing tissue. While it is well known …

OBJECTIVE Acromegalic patients have increased mortality from vascular diseases.
Although atherosclerotic risk factors such as hypertension, diabetes mellitus and …

Abstract Objective and Design Eighteen active acromegalics entered a prospective open
study with cabergoline (CAB), a dopaminergic drug much more potent than bromocriptine …

Objective: The purpose of this study was to define safety and efficacy of medical therapy in
the treatment of nonfunctioning pituitary tumours. Design: We studied thirteen patients with a …

Acromegaly is a severe slow-developing disease associated with a poor prognosis for
cardiovascular disease. To evaluate the impact of age and gender on the severity of the …

Background The excess mortality and morbidity associated with acromegaly are secondary
to prolonged elevation of GH and IGF-I. Vigorous control of these biochemical parameters …

Objective To evaluate the role of age, gender, duration and control of acromegaly on the
reversibility of arthropathy. Patients and Design 30 de novo patients with active acromegaly …

Background Cardiac abnormalities develop in patients with acromegaly as a consequence
of effects of GH/IGF-I on the heart and related cardiovascular risk factors. Objective To …

The aim of this study was to evaluate the efficacy of a 6-month treatment with lanreotide
(LAN)(60–90 mg/month) alone and combined with cabergoline (CAB)(1.5-3 mg/week) in 10 …

Criteria to define the biochemical remission of acromegaly following surgery have changed
over the years, and the current use of stringent criteria needs a critical re-evaluation of the …